Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Hosted on MSN24d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Post-hoc analysis revealed variability in placebo response, highlighting trial design challenges for future studies. On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from ...
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...
Vertex Pharmaceuticals (VRTX ... Vertex is expected to post earnings of $4 per share for the current quarter, representing a year-over-year change of -4.8%. Over the last 30 days, the Zacks ...
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.
Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new ... She has a master's degree in English literature and post graduate diploma in broadcast journalism. Future of Healthcategory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback